Medtronic Announces FDA Approval of Protecta™ Implantable Defibrillators That Reduce Inappropriate Shocks

New Implantable Cardiac Devices with SmartShockTechnology Enhance Patient Quality of Life

MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Protecta™ portfolio of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds). The new family of implantable defibrillators features SmartShock™ Technology, which includes six new Medtronic-exclusive algorithms that recognize life-threatening arrhythmias and deliver therapeutic shocks only when appropriate,¹ therefore enhancing patient quality of life.2 Findings from the Virtual ICD study, based on a statistical model, shows that 98 percent of patients with SmartShock Technology will be free of inappropriate shocks one year after implant and 92 percent will be free of inappropriate shocks five years after implant.1 Shipments of the Protecta portfolio of products will begin immediately.

“With recent studies showing that up to one in five patients may experience inappropriate shocks, this new technology can significantly mitigate that concern and will have a real-world impact on my patients’ lives by improving quality of life,” said Kent Volosin, M.D., cardiologist at the University of Pennsylvania in Philadelphia.

Implantable defibrillators are designed to provide lifesaving shocks or painless pacing to stop life-threatening fast or irregular heart beats, also known as ventricular arrhythmias, which can lead to sudden cardiac death. Sudden cardiac death kills more people each year than lung cancer, breast cancer and HIV/AIDS combined.3,4 Medtronic estimates more than 70,000 lives have been saved worldwide by implantable defibrillators over the past five years.5

While the majority of shocks delivered are necessary to treat potentially fatal arrhythmias, studies estimate that up to 20 percent of patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device.6, 7, 8, 9 Additionally, data show that 61 percent of patients who received an inappropriate shock visited the hospital, clinic or emergency room at least once within three days of receiving therapy.10

“The Protecta family of devices addresses one of physicians’ top needs—allowing them to better serve patients by providing devices that are designed to deliver a shock only when needed to save a life,” said Pat Mackin, president of the Cardiac Rhythm Disease Management business and senior vice president at Medtronic. “This new innovation is the latest example of Medtronic’s 20-year leadership in shock reduction technology through product innovation backed by industry-leading clinical research.”

Medtronic has supported eight major shock reduction clinical trials (Shock-Less, PREPARE, PainFree Rx I and II, PainFree SST, WAVE, ADVANCE III and EMPIRIC). In total, these trials included more than 5,500 patients worldwide—more than any other device manufacturer.

About SmartShock Technology
The Protecta implantable defibrillators include SmartShock Technology, six new Medtronic-exclusive solutions, five of which were not previously available. The algorithms are automatically on when implanted and address the industry-wide issue of inappropriate shocks. They include:

  • Wavelet + PR Logic, SVT discrimination in the VF zone, and Confirmation + in Protecta devices are designed to detect non-lethal arrhythmias and deliver lifesaving shock therapy only when necessary.
  • T-wave Discrimination and Lead Noise Discrimination distinguish oversensing from deadly arrhythmias and withhold shock therapy when appropriate.
  • Lead Integrity Alert, first released in 2008, provides advanced warning of potential lead fractures so the patient can seek medical attention, and reduces the risk of receiving an inappropriate shock.

About Protecta
All Protecta XT devices have OptiVol® 2.0 Fluid Status Monitoring, a new update on the Medtronic-exclusive feature that measures changes in fluid build-up in heart failure patients to identify patients at risk of worsening heart failure.11 Medtronic implantable defibrillators have Conexus® Wireless Telemetry that allows patients to transmit device data to a physician’s clinic from virtually anywhere via the industry’s largest remote monitoring system, the Medtronic CareLink® Network. CareLink serves more than 4,000 clinics and 500,000 patients in 30 countries.

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1Volosin et al. “Virtual ICD: A Model to Evaluate Shock Reduction Strategies.” Heart Rhythm. Vol. 7, N. 5, May supplement 2010. (PO3-125).
2Wathen MS, et al. Circulation. 2004;110:2591-2596.
3American Cancer Society. Cancer Facts and Figures. 2006.
4CIA. The World Fact Book – Rank Order – HIV/AIDS – deaths. Available at http://www.cia.gov.
5Medtronic data on file. 2010.
6Kadish A, Dyer A, Daubert JP, et al., for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. May 20, 2004;350(21):2151-2158.
7Daubert JP, Zareba W, Cannom DS, et al., for the MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. April 8, 2008;51(14):1357-1365.
8Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. September 4, 2008;359(10):1009-1017.
9Mitka M. New study supports lifesaving benefits of implantable defibrillation devices. JAMA. July 8, 2009;302(2):134-135.
10Sweeney et al. “Differences in Effects of Electrical Therapy Type on Health Care Utilization in the MVP ICD Trial” Heart Rhythm Society, May 2010
11Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF Study. J Am Coll Cardiol, April 27,2010,55(17):1803-1810.



CONTACT:

Medtronic, Inc.
Wendy Dougherty
Public Relations
763-526-2853
or
Jeff Warren
Investor Relations
763-505-2696

KEYWORDS:   United States  North America  Minnesota  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Clinical Trials  Hospitals  Medical Devices  Manufacturing  Chemicals/Plastics  Engineering  Research  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.